George Medicines

George Medicines is a venture-backed, private biotech company founded in 2018 as a spin-out from George Health and The George Institute for Global Health. It employs a de-risked, late-stage development model by creating single-pill combinations of approved drugs, with its lead program, GMRx2 for hypertension, in Phase 3 and actively securing global commercialization partnerships. The company's strategy is to accelerate time-to-market for therapies that address leading causes of death like hypertension and diabetes, focusing on both developed and developing world markets through a partnership-driven commercial approach.

Proprietary formulation platform for developing single-pill, multi-mechanism fixed-dose combinations (FDCs) of existing, approved medicines, focusing on optimized and low-dose regimens.

The hypertension and diabetes markets are crowded with generics and branded therapies. Competition comes from other companies developing fixed-dose combinations (e.g., polypills for cardiovascular prevention) and from entrenched treatment protocols. George Medicines differentiates by focusing on low-dose, triple-combination pills early in the treatment pathway and targeting both developed and developing world markets.